| 27.95 -0.99 (-3.42%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.41  |
1-year : | 47.85 |
| Resists | First : | 35.45 |
Second : | 40.97 |
| Pivot price | 32.14 |
|||
| Supports | First : | 26.54 |
Second : | 22.08 |
| MAs | MA(5) : | 28.87 |
MA(20) : | 33.75 |
| MA(100) : | 30.69 |
MA(250) : | 19.35 |
|
| MACD | MACD : | -2.2 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 11 |
D(3) : | 7.6 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 44.88 | Low : | 4.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MBX ] has closed above bottom band by 14.7%. Bollinger Bands are 17.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.72 - 28.88 | 28.88 - 29.06 |
| Low: | 26.11 - 26.28 | 26.28 - 26.46 |
| Close: | 27.61 - 27.92 | 27.92 - 28.26 |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Thu, 12 Mar 2026
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Thu, 12 Mar 2026
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com
Wed, 25 Feb 2026
UBS Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Feb 2026 - Meyka
Thu, 05 Feb 2026
MBX Biosciences raises $87.1 million through at-the-market stock offering - Investing.com
Thu, 05 Feb 2026
MBX Biosciences Raises $87 Million in ATM Offering - TipRanks
Fri, 26 Sep 2025
MBX Biosciences Announces Public Offering Agreement - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 108 (%) |
| Shares Short | 2,200 (K) |
| Shares Short P.Month | 2,310 (K) |
| EPS | 7.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -24.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | 3.64 |
| PEG Ratio | 0 |
| Price to Book value | 3.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|